Immunotherapy setback for AstraZeneca – Seeking Alpha
|
Immunotherapy setback for AstraZeneca
Seeking Alpha AstraZeneca (NYSE:AZN) -15% premarket after the trial of its new lung cancer drug failed to reach its “endpoints” for progression free survival – the length for which people go without their condition worsening. The study, known as Mystic, featured an … |
WhaTech |
Stem cell-based method selectively targets cancerous tissue while preventing toxic side effects
News-Medical.net A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a more localized way. Weian Zhao … Tumor Tissue Stiffness Exploited for MSC or Potentially CAR T-Cell TherapeuticsGenetic Engineering & Biotechnology News Mesenchymal stem cells market grows with increasing clinical application for the treatment of chronic disease …WhaTech Circulating Tumor Cells and Cancer Stem Cells Market Foreseen to Grow Exponentially Over 2017 – 2025MilTech |
|
Immunotherapy research in B’luru gaining momentum
The New Indian Express iCREST, the HCG wing for cellular therapies (immunotherapy), is currently carrying out work targeting it for patients who have failed first line therapies or have contraindications, he said. (A contraindication is a situation in which a drug, procedure … |